Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating and a price target of $12. The analyst says the topline registrational data (expected in mid-2023) from the UPLIFT...
Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating and a price target of $12. The analyst says the topline registrational data (expected in mid-2023) from the UPLIFT...